17,261 trials
Epilepsy
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) From Visit 1 to the End of Study (Approximately 61 Weeks) — 37 participants
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: PFS Rate — 30 percentage of participants
Brainstem Glioma
Primary: Progression-free Survival — 4.9 Months
Leukemia · AML · MDS
Primary: Participants With a Complete Response — 34 Participants
Acne · Scar
Primary: Overall Improvement of Acne Scarring — 2.26; 1.91 units on a scale
Pancreatic Neoplasms
Primary: Maximal Tolerated Dose (MTD) & Dose Limiting Toxicity (DLT) of Intratumoral Injections of BC-819 — 0; 1 participants
Graft-versus-Host Disease
Primary: Response to Bortezomib (VELCADE®) — 2; 2; 4 participants
Lung Cancer Prevention
Primary: Change in Urinary 8-hydroxydeoxyguanosine Levels — 2.36; 5.20; -1.08 ng/mg creatinine
Fallopian Tube Cancer · Ovarian Sarcoma · Ovarian Stromal Cancer
Primary: Acute Toxicity Rate — 6 percentage of participants
Biliary Tract Cancer · Gallbladder Cancer · Cancer Of The Extrahepatic Bile Duct
Primary: Progression Free Survival — 105; 114; 148 days
Hemostasis · Oral Contraceptive
Primary: Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels — 45.0; 56.8 pmol/L — p=0.5892
Acute Undifferentiated Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only) — 7.8 10^9 Neutrophils per Liter
Metastatic Prostate Cancer
Primary: Maximum Tolerated Dose (MTD) of Dasatinib Administered With Docetaxel — NA mg
Cocaine Addiction · Cocaine-related Disorder · Executive Dysfunction
Primary: Abstinence — 71.4; 16.6 percentage of participants
Alcohol Dependence · Executive Dysfunction · Abnormal Craving for Drugs
Primary: Use of Alcohol — 15; 8 participants